ClinicalTrials.gg
Active, not recruitingNCT03932331Updated Apr 20, 2026Results posted

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

A Phase 1/2 interventional study of Acalabrutinib in Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma and Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia, sponsored by AstraZeneca. Active, not recruiting at 23 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
105
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell — 5 open to participants now, 20 under way, 1 of them phase 3. acalabrutinib · Lymphoma, Mantle-Cell.

Enrollment
6th of 26
105 · median 49
Started
2020
with 4 others
Phase 1/2
3 of 26
1 open now
Primary completion
2022-12
later than 3 of 19 live
Registered
7th of 26
by date
Lead sponsor
4 of 26
AstraZeneca

Among the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, this one is the 6th largest by enrollment, is one of 5 that started in 2020, is one of 3 in phase 1/2, reaches primary completion later than 3 of the 19 other live ones, and was the 7th registered.

Lymphoma, Mantle-Cell

1,220 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

5 of the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This is an open-label, two-part study to assess the safety, tolerability, pharmacokinetics and clinical efficacy of acalabrutinib in Chinese adult subjects with R/R MCL, CLL and other B-cell malignancies. The study is divided into 2 parts: Phase 1 portion and Phase 2 portion.

03

Conditions studied

  • Phase I: Relapsed or Refractory B-cell Malignancies
  • Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma
  • Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. Chinese subjects at least 18 years of age at the time of study entry.
  3. (ECOG) performance status of ≤2
  4. Adequate hematological and organ function.
  5. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid .
  6. confirmed MCL, with documentation of chromosome translocation t(11;14) (q13;q32) and/or overexpression of cyclin D1 in association with other relevant markers (eg, CD5, CD19, CD20, PAX5). Disease had after or been refractory to previous treatment.
  7. Diagnosis of CLL that meets published diagnostic criteria. Must have received ≥ 1 prior systemic therapies for CLL.
  8. Active disease per iwCLL 2018 criteria that requires treatment. (CLL only)
  9. Other relapsed/refractory B-cell malignancies without stand of care (phase 1 only).

Exclusion criteria

Exclusion criteria

  1. Prior , except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject had been disease free for ≥2 years or which would not have limited survival to \<2 years.
  2. Significant cardiovascular disease.
  3. Known central nervous system involvement of lymphoma/leukemia or .
  4. Known history of , serologic status reflecting active or C infection.
  5. Major surgery within 4 weeks before first dose of study drugs.
  6. Uncontrolled hemolytic anemia or idiopathic thrombocytopenia purpura.
  7. Required or received anticoagulation with warfarin or equivalent vitamin K antagonist (eg, phenprocoumon).
  8. Prior exposure to a BCR or BCL-2 inhibitor.
  9. Use of a strong inhibitor or inducer of .
  10. Breastfeeding or pregnant.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Acalabrutinib

    Acalabrutinib will be orally administered until disease progression or unacceptable toxicity.

    Drug: Acalabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Phase I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. A SAE is an AE occurring during any study phase, that fulfils 1 or more of the following criteria: death, life-threatening, in-participant hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital abnormality or birth defect, and an important medical event that may jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AEs leading to discontinuation of acalabrutinib were those with action taken was 'Drug Permanently Discontinued' for acalabrutinib.

    Time frame: From the first dose administration up to 30 days following the date of last dose of study treatment, approximately 25 months.

  2. Phase I: Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUCinf) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

    Blood samples were collected to determine the AUCinf of acalabrutinib and ACP-5862 in plasma. The AUCinf was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1

  3. Phase I: Area Under the Plasma Concentration-Time Curve From Zero to 12 Hours (AUC0-12) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

    Blood samples were collected to determine the AUC0-12 of acalabrutinib and ACP-5862 in plasma. The AUC0-12 was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1

  4. Phase I: Area Under the Plasma Concentration-Time Curve From Zero to the Time of the Last Quantifiable Concentration (AUClast) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

    Blood samples were collected to determine the AUClast of acalabrutinib and ACP-5862 in plasma. The AUClast was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1

  5. Phase I: Maximum Observed Plasma Drug Concentration (Cmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib

    Blood samples were collected to determine the Cmax of acalabrutinib and ACP-5862 in plasma. The Cmax was determined using non-compartmental method.

    Time frame: Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8

  6. Phase I: Time to Reach Maximum Observed Concentration (Tmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib

    Blood samples were collected to determine the tmax of acalabrutinib and ACP-5862 in plasma. The tmax was determined using non-compartmental method.

    Time frame: Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8

  7. Phase I: Apparent Total Body Clearance of Drug (CL/F) of Acalabrutinib Post Single and Multiple Dose of Acalabrutinib

    Urine samples were collected to determine the CL/F of acalabrutinib. The CL/F was determined using non-compartmental method.

    Time frame: Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8

  8. Phase I: Apparent Volume of Distribution (Vz/F) of Acalabrutinib Post Single Dose of Acalabrutinib

    Blood samples were collected to determine the Vz/F of acalabrutinib in plasma. The Vz/F was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1

  9. Phase I: Terminal Elimination Rate Constant (λz) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

    Blood samples were collected to determine the λz of acalabrutinib and ACP-5862 in plasma. The λz was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1

  10. Phase I: Terminal Phase Half-Life (t1/2λz) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

    Blood samples were collected to determine the t1/2λz of acalabrutinib and ACP-5862 in plasma. The t1/2λz was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1

  11. Phase I: Metabolite/Parent Drug Cmax Ratio (MRCmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib

    Blood samples were collected to determine the MRCmax of acalabrutinib and ACP-5862 in plasma. The MRCmax was determined using non-compartmental method.

    Time frame: Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8

  12. Phase I: Metabolite/Parent Drug AUC Ratio (MRAUCinf) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

    Blood samples were collected to determine the MRAUCinf of acalabrutinib in plasma. The MRAUCinf was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1

  13. Phase I: Area Under the Plasma Concentration-Time Curve Across the Dosing Interval (AUCτ) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

    Blood samples were collected to determine the AUCτ of acalabrutinib and ACP-5862 in plasma. The AUCτ was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8

  14. Phase I: Minimum Observed Plasma Drug Concentration (Cmin) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

    Blood samples were collected to determine the Cmin of acalabrutinib and ACP-5862 in plasma. The Cmin was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8

  15. Phase I: Metabolite/Parent Drug AUCτ Ratio (MRAUCτ) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

    Blood samples were collected to determine the MRAUCτ of acalabrutinib and ACP-5862 in plasma. The MRAUCτ was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8

  16. Phase I: Temporal Change Parameter (TCP) in Systemic Exposure of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

    Blood samples were collected to determine the TCP of acalabrutinib and ACP-5862 in plasma. The TCP in systemic exposure was calculated as AUCτ (steady state)/AUCinf (first dose). The TCP was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8

  17. Phase I: Accumulation Ratio of AUCτ (Rac AUC) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

    Blood samples were collected to determine the Rac AUC of acalabrutinib and ACP-5862 in plasma. The Rac AUC was calculated as AUCτ (steady state)/AUCτ (first dose). The Rac AUC was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8

  18. Phase I: Accumulation Ratio of Cmax (Rac Cmax) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

    Blood samples were collected to determine the Rac Cmax of acalabrutinib and ACP-5862 in plasma. The Rac Cmax was calculated as Cmax (steady state)/Cmax (first dose). The Rac Cmax was determined using non-compartmental method.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8

  19. Phase II: Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR)

    The ORR \[based on International workshop on chronic lymphocytic leukemia (iwCLL) 2018 criteria as assessed by the BICR\] was defined as the percentage of participants who achieved a complete response (CR), CR with incomplete marrow recovery (CRi), nodular partial response (nPR), and partial response (PR). The ORR and the corresponding 95% 2-sided confidence interval (CI) of ORR were presented based on Clopper-Pearson exact method.

    Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.

Secondary outcomes

  1. Phase I: Best Overall Response (BOR) Assessed by Investigator in Participants With R/R CLL

    The BOR is best response a participant has had following first dose date but prior to starting any subsequent anticancer therapy up to and including progression or last evaluable assessment in absence of progression. The CR: No lymph nodes \>=1.5 centimeters. The CRi: Participants who fulfill all criteria for CR but have a persistent anemia, thrombocytopenia or neutropenia apparently unrelated to CLL but related to drug toxicity. The nPR: Participants who were in a complete remission but bone marrow nodules can be identified histologically. The PR: Disease \>=50% from baseline. Partial response with lymphocytosis (PRL): Presence of lymphocytosis plus \>=50% reduction in lymphadenopathy and/or in spleen or liver enlargement plus 1 of PR criteria for platelets or hemoglobin must be met. Stable disease (SD): Change of -49% to +49% in lymph nodes. PD: Increase \>=50% from baseline or from response.

    Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days thereafter or more frequently at the investigator's discretion, approximately 25 months

  2. Phase I: Best Overall Response Assessed by Investigator in Participants With R/R MCL

    The BOR is best response a participant has had following first dose date but prior to starting any subsequent anticancer therapy up to and including progression or last evaluable assessment in absence of progression. CR: No lymph nodes \>=1.5 centimeters. PR: Disease \>=50% from baseline. SD: Change of -49% to +49% in lymph nodes. PD: Increase \>=50% from baseline or from response.

    Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days thereafter or more frequently at the investigator's discretion, approximately 25 months

  3. Phase II: ORR Assessed by Investigator

    The ORR (based on iwCLL 2018 criteria as assessed by the Investigator) was defined as the percentage of participants who achieved a CR, CRi, nPR, and PR. The ORR and the corresponding 95% 2-sided CI of ORR were presented based on Clopper-Pearson exact method.

    Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.

  4. Phase II: Duration of Response (DoR) Assessed by BICR and Investigator

    The DoR (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval from the first documentation of objective response to the earlier of the first documentation of objective PD or death from any cause. The DoR was calculated using Kaplan-Meier technique.

    Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.

  5. Phase II: Progression-Free Survival (PFS) Assessed by BICR and Investigator

    The PFS (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval from the start of acalabrutinib therapy to the earlier of the first documentation of objective PD or death from any cause. The PFS was calculated using Kaplan-Meier technique.

    Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.

  6. Phase II: Time to Response (TTR) Assessed by BICR and Investigator

    The TTR (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval between the date of first dose and the date of initial documentation of a response.

    Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.

  7. Phase II CLL Only: Time to Next Treatment (TTNT)

    The TTNT was defined as the interval from the start of acalabrutinib therapy to institution of non-protocol specified anticancer treatment for CLL or death due to any cause, whichever came first. The TTNT was calculated using Kaplan-Meier technique.

    Time frame: Response evaluations performed every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.

  8. Phase II CLL Only: Percentage of Participants With Minimal Residual Disease (MRD) Negativity

    The MRD negative rate was defined as the percentage of participants with MRD-negativity (\<1 CLL cell per 10000 leukocytes) measured in the peripheral blood by flow cytometry.

    Time frame: At screening (-28 days) and end of treatment visit. Assessed until 18 December 2023.

  9. Phase II: Percentage of Participants With Overall Survival (OS) at Month 6

    The OS was defined as the interval from the start of acalabrutinib therapy to death from any cause. The OS was calculated using Kaplan-Meier technique.

    Time frame: From the first dose administration up to Month 6

  10. Phase II: Plasma Concentration of Acalabrutinib

    Blood samples were collected to determine the plasma concentration of acalabrutinib.

    Time frame: At 1, 2 and 4 hours post-dose on Day 8, 15 and 22 of Cycle 1

07

Results

Posted Mar 20, 2025

Participant flow

This Phase I/II open-label study was conducted in participants with relapsed/refractory (R/R) mantle cell lymphoma (MCL), R/R chronic lymphocytic leukemia (CLL) or other B-cell malignancies at 20 study centers in China. The Phase II CLL results are reported for analysis with assessment until data cut-off (DCO) date of 18 December 2023. PD= Progressive disease.

Participant flow — Overall Study
MilestonePhase IPhase II MCLPhase II CLL
Started123360
Participants from phase i who entered phase ii mcl010
Completed000
Not completed123360
Withdrew: Death072
Withdrew: Withdrawal by subject030
Withdrew: Meet the point of final analysis for this cohort8230
Withdrew: Progressive disease300
Withdrew: Lung infection100
Withdrew: Other0058

Outcome measures

PrimaryPhase I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. A SAE is an AE occurring during any study phase, that fulfils 1 or more of the following criteria: death, life-threatening, in-participant hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital abnormality or birth defect, and an important medical event that may jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AEs leading to discontinuation of acalabrutinib were those with action taken was 'Drug Permanently Discontinued' for acalabrutinib.

Time frame:
From the first dose administration up to 30 days following the date of last dose of study treatment, approximately 25 months.
Reported as:
Count of participants · Participants
Phase I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPhase I
Any AE12
Any SAE2
Any AE leading to discontinuation of Acalabrutinib1
Any AE with outcome death0
PrimaryPhase I: Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUCinf) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

Blood samples were collected to determine the AUCinf of acalabrutinib and ACP-5862 in plasma. The AUCinf was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Phase I: Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUCinf) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
hour*nanogram per milliliter (h*ng/mL)Phase I
Acalabrutinib1351 ± 47.99
ACP-58622421 ± 29.46
PrimaryPhase I: Area Under the Plasma Concentration-Time Curve From Zero to 12 Hours (AUC0-12) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

Blood samples were collected to determine the AUC0-12 of acalabrutinib and ACP-5862 in plasma. The AUC0-12 was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1
Reported as:
Geometric mean · h*ng/mL
Phase I: Area Under the Plasma Concentration-Time Curve From Zero to 12 Hours (AUC0-12) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
h*ng/mLPhase I
Acalabrutinib1310 ± 50.39
ACP-58622008 ± 37.76
PrimaryPhase I: Area Under the Plasma Concentration-Time Curve From Zero to the Time of the Last Quantifiable Concentration (AUClast) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

Blood samples were collected to determine the AUClast of acalabrutinib and ACP-5862 in plasma. The AUClast was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Reported as:
Geometric mean · h*ng/mL
Phase I: Area Under the Plasma Concentration-Time Curve From Zero to the Time of the Last Quantifiable Concentration (AUClast) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
h*ng/mLPhase I
Acalabrutinib1343 ± 48.40
ACP-58622270 ± 32.82
PrimaryPhase I: Maximum Observed Plasma Drug Concentration (Cmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib

Blood samples were collected to determine the Cmax of acalabrutinib and ACP-5862 in plasma. The Cmax was determined using non-compartmental method.

Time frame:
Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Reported as:
Geometric mean · ng/mL
Phase I: Maximum Observed Plasma Drug Concentration (Cmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib
ng/mLPhase I
Post single dose: Acalabrutinib967.6 ± 59.52
Post single dose: ACP-5862628.1 ± 46.38
Post multiple dose: Acalabrutinib958.2 ± 60.99
Post multiple dose: ACP-5862710.0 ± 38.08
PrimaryPhase I: Time to Reach Maximum Observed Concentration (Tmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib

Blood samples were collected to determine the tmax of acalabrutinib and ACP-5862 in plasma. The tmax was determined using non-compartmental method.

Time frame:
Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Reported as:
Median · hour
Phase I: Time to Reach Maximum Observed Concentration (Tmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib
hourPhase I
Post single dose: Acalabrutinib0.50 (0.48 to 1.02)
Post single dose: ACP-58620.88 (0.73 to 2.00)
Post multiple dose: Acalabrutinib0.50 (0.27 to 2.03)
Post multiple dose: ACP-58621.00 (0.73 to 3.95)
PrimaryPhase I: Apparent Total Body Clearance of Drug (CL/F) of Acalabrutinib Post Single and Multiple Dose of Acalabrutinib

Urine samples were collected to determine the CL/F of acalabrutinib. The CL/F was determined using non-compartmental method.

Time frame:
Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Reported as:
Geometric mean · liter per hour
Phase I: Apparent Total Body Clearance of Drug (CL/F) of Acalabrutinib Post Single and Multiple Dose of Acalabrutinib
liter per hourPhase I
Post single dose74.01 ± 36.77
Post multiple dose72.81 ± 45.25
PrimaryPhase I: Apparent Volume of Distribution (Vz/F) of Acalabrutinib Post Single Dose of Acalabrutinib

Blood samples were collected to determine the Vz/F of acalabrutinib in plasma. The Vz/F was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Reported as:
Geometric mean · liter
Phase I: Apparent Volume of Distribution (Vz/F) of Acalabrutinib Post Single Dose of Acalabrutinib
literPhase I
Phase I: Apparent Volume of Distribution (Vz/F) of Acalabrutinib Post Single Dose of Acalabrutinib171.3 ± 105.5
PrimaryPhase I: Terminal Elimination Rate Constant (λz) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

Blood samples were collected to determine the λz of acalabrutinib and ACP-5862 in plasma. The λz was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Reported as:
Geometric mean · 1/hour
Phase I: Terminal Elimination Rate Constant (λz) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
1/hourPhase I
Acalabrutinib0.43212 ± 51.085
ACP-58620.096102 ± 19.036
PrimaryPhase I: Terminal Phase Half-Life (t1/2λz) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

Blood samples were collected to determine the t1/2λz of acalabrutinib and ACP-5862 in plasma. The t1/2λz was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Reported as:
Geometric mean · hour
Phase I: Terminal Phase Half-Life (t1/2λz) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
hourPhase I
Acalabrutinib1.604 ± 76.21
ACP-58627.213 ± 28.03
PrimaryPhase I: Metabolite/Parent Drug Cmax Ratio (MRCmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib

Blood samples were collected to determine the MRCmax of acalabrutinib and ACP-5862 in plasma. The MRCmax was determined using non-compartmental method.

Time frame:
Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Reported as:
Geometric mean · ratio
Phase I: Metabolite/Parent Drug Cmax Ratio (MRCmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib
ratioPhase I
Post single dose0.6276 ± 37.87
Post multiple dose0.7662 ± 43.08
PrimaryPhase I: Metabolite/Parent Drug AUC Ratio (MRAUCinf) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib

Blood samples were collected to determine the MRAUCinf of acalabrutinib in plasma. The MRAUCinf was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Reported as:
Geometric mean · ratio
Phase I: Metabolite/Parent Drug AUC Ratio (MRAUCinf) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
ratioPhase I
Phase I: Metabolite/Parent Drug AUC Ratio (MRAUCinf) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib1.732 ± 31.55
PrimaryPhase I: Area Under the Plasma Concentration-Time Curve Across the Dosing Interval (AUCτ) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

Blood samples were collected to determine the AUCτ of acalabrutinib and ACP-5862 in plasma. The AUCτ was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Reported as:
Geometric mean · h*ng/mL
Phase I: Area Under the Plasma Concentration-Time Curve Across the Dosing Interval (AUCτ) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
h*ng/mLPhase I
Acalabrutinib1373 ± 43.62
ACP-58622707 ± 28.61
PrimaryPhase I: Minimum Observed Plasma Drug Concentration (Cmin) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

Blood samples were collected to determine the Cmin of acalabrutinib and ACP-5862 in plasma. The Cmin was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Reported as:
Geometric mean · ng/mL
Phase I: Minimum Observed Plasma Drug Concentration (Cmin) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
ng/mLPhase I
Acalabrutinib2.443 ± 148.0
ACP-586237.52 ± 37.58
PrimaryPhase I: Metabolite/Parent Drug AUCτ Ratio (MRAUCτ) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

Blood samples were collected to determine the MRAUCτ of acalabrutinib and ACP-5862 in plasma. The MRAUCτ was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Reported as:
Geometric mean · ratio
Phase I: Metabolite/Parent Drug AUCτ Ratio (MRAUCτ) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
ratioPhase I
Phase I: Metabolite/Parent Drug AUCτ Ratio (MRAUCτ) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib1.906 ± 33.26
PrimaryPhase I: Temporal Change Parameter (TCP) in Systemic Exposure of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

Blood samples were collected to determine the TCP of acalabrutinib and ACP-5862 in plasma. The TCP in systemic exposure was calculated as AUCτ (steady state)/AUCinf (first dose). The TCP was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Reported as:
Geometric mean · ratio
Phase I: Temporal Change Parameter (TCP) in Systemic Exposure of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
ratioPhase I
Acalabrutinib1.017 ± 37.57
ACP-58621.118 ± 17.15
PrimaryPhase I: Accumulation Ratio of AUCτ (Rac AUC) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

Blood samples were collected to determine the Rac AUC of acalabrutinib and ACP-5862 in plasma. The Rac AUC was calculated as AUCτ (steady state)/AUCτ (first dose). The Rac AUC was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Reported as:
Geometric mean · ratio
Phase I: Accumulation Ratio of AUCτ (Rac AUC) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
ratioPhase I
Acalabrutinib1.048 ± 37.97
ACP-58621.348 ± 41.64
PrimaryPhase I: Accumulation Ratio of Cmax (Rac Cmax) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib

Blood samples were collected to determine the Rac Cmax of acalabrutinib and ACP-5862 in plasma. The Rac Cmax was calculated as Cmax (steady state)/Cmax (first dose). The Rac Cmax was determined using non-compartmental method.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Reported as:
Geometric mean · ratio
Phase I: Accumulation Ratio of Cmax (Rac Cmax) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
ratioPhase I
Acalabrutinib0.8218 ± 59.99
ACP-58621.130 ± 70.23
PrimaryPhase II: Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR)

The ORR \[based on International workshop on chronic lymphocytic leukemia (iwCLL) 2018 criteria as assessed by the BICR\] was defined as the percentage of participants who achieved a complete response (CR), CR with incomplete marrow recovery (CRi), nodular partial response (nPR), and partial response (PR). The ORR and the corresponding 95% 2-sided confidence interval (CI) of ORR were presented based on Clopper-Pearson exact method.

Time frame:
Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Reported as:
Number · percentage of participants
Phase II: Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR)
percentage of participantsPhase II MCLPhase II CLL
Phase II: Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR)82.4 (65.5 to 93.2)86.7 (75.4 to 94.1)
SecondaryPhase I: Best Overall Response (BOR) Assessed by Investigator in Participants With R/R CLL

The BOR is best response a participant has had following first dose date but prior to starting any subsequent anticancer therapy up to and including progression or last evaluable assessment in absence of progression. The CR: No lymph nodes \>=1.5 centimeters. The CRi: Participants who fulfill all criteria for CR but have a persistent anemia, thrombocytopenia or neutropenia apparently unrelated to CLL but related to drug toxicity. The nPR: Participants who were in a complete remission but bone marrow nodules can be identified histologically. The PR: Disease \>=50% from baseline. Partial response with lymphocytosis (PRL): Presence of lymphocytosis plus \>=50% reduction in lymphadenopathy and/or in spleen or liver enlargement plus 1 of PR criteria for platelets or hemoglobin must be met. Stable disease (SD): Change of -49% to +49% in lymph nodes. PD: Increase \>=50% from baseline or from response.

Time frame:
Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days thereafter or more frequently at the investigator's discretion, approximately 25 months
Reported as:
Count of participants · Participants
Phase I: Best Overall Response (BOR) Assessed by Investigator in Participants With R/R CLL
ParticipantsPhase I
CR0
CRi0
nPR0
PR4
PRL0
SD0
PD0
Not evaluable0
SecondaryPhase I: Best Overall Response Assessed by Investigator in Participants With R/R MCL

The BOR is best response a participant has had following first dose date but prior to starting any subsequent anticancer therapy up to and including progression or last evaluable assessment in absence of progression. CR: No lymph nodes \>=1.5 centimeters. PR: Disease \>=50% from baseline. SD: Change of -49% to +49% in lymph nodes. PD: Increase \>=50% from baseline or from response.

Time frame:
Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days thereafter or more frequently at the investigator's discretion, approximately 25 months
Reported as:
Count of participants · Participants
Phase I: Best Overall Response Assessed by Investigator in Participants With R/R MCL
ParticipantsPhase I
CR1
PR4
SD0
PD3
Not evaluable0
SecondaryPhase II: ORR Assessed by Investigator

The ORR (based on iwCLL 2018 criteria as assessed by the Investigator) was defined as the percentage of participants who achieved a CR, CRi, nPR, and PR. The ORR and the corresponding 95% 2-sided CI of ORR were presented based on Clopper-Pearson exact method.

Time frame:
Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Reported as:
Number · percentage of participants
Phase II: ORR Assessed by Investigator
percentage of participantsPhase II MCLPhase II CLL
Phase II: ORR Assessed by Investigator73.5 (55.6 to 87.1)85.0 (73.4 to 92.9)
SecondaryPhase II: Duration of Response (DoR) Assessed by BICR and Investigator

The DoR (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval from the first documentation of objective response to the earlier of the first documentation of objective PD or death from any cause. The DoR was calculated using Kaplan-Meier technique.

Time frame:
Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Reported as:
Median · months
Phase II: Duration of Response (DoR) Assessed by BICR and Investigator
monthsPhase II MCLPhase II CLL
BICR AssessmentNA (6.4 to NA)NA (25.00 to NA)
Investigator AssessmentNA (11.2 to NA)NA (26.38 to NA)
SecondaryPhase II: Progression-Free Survival (PFS) Assessed by BICR and Investigator

The PFS (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval from the start of acalabrutinib therapy to the earlier of the first documentation of objective PD or death from any cause. The PFS was calculated using Kaplan-Meier technique.

Time frame:
Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Reported as:
Median · months
Phase II: Progression-Free Survival (PFS) Assessed by BICR and Investigator
monthsPhase II MCLPhase II CLL
BICR AssessmentNA (5.55 to NA)NA (28.32 to NA)
Investigator AssessmentNA (5.55 to NA)NA (30.62 to NA)
SecondaryPhase II: Time to Response (TTR) Assessed by BICR and Investigator

The TTR (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval between the date of first dose and the date of initial documentation of a response.

Time frame:
Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Reported as:
Median · months
Phase II: Time to Response (TTR) Assessed by BICR and Investigator
monthsPhase II MCLPhase II CLL
BICR Assessment1.8 (1.6 to 3.7)5.06 (2.7 to 16.6)
Investigator Assessment1.9 (1.6 to 3.7)5.52 (2.7 to 22.2)
SecondaryPhase II CLL Only: Time to Next Treatment (TTNT)

The TTNT was defined as the interval from the start of acalabrutinib therapy to institution of non-protocol specified anticancer treatment for CLL or death due to any cause, whichever came first. The TTNT was calculated using Kaplan-Meier technique.

Time frame:
Response evaluations performed every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Reported as:
Median · months
Phase II CLL Only: Time to Next Treatment (TTNT)
monthsPhase II CLL
Phase II CLL Only: Time to Next Treatment (TTNT)NA (NA to NA)
SecondaryPhase II CLL Only: Percentage of Participants With Minimal Residual Disease (MRD) Negativity

The MRD negative rate was defined as the percentage of participants with MRD-negativity (\<1 CLL cell per 10000 leukocytes) measured in the peripheral blood by flow cytometry.

Time frame:
At screening (-28 days) and end of treatment visit. Assessed until 18 December 2023.
Reported as:
Number · percentage of participants
Phase II CLL Only: Percentage of Participants With Minimal Residual Disease (MRD) Negativity
percentage of participantsPhase II CLL
Phase II CLL Only: Percentage of Participants With Minimal Residual Disease (MRD) Negativity0
SecondaryPhase II: Percentage of Participants With Overall Survival (OS) at Month 6

The OS was defined as the interval from the start of acalabrutinib therapy to death from any cause. The OS was calculated using Kaplan-Meier technique.

Time frame:
From the first dose administration up to Month 6
Reported as:
Number · percentage of participants
Phase II: Percentage of Participants With Overall Survival (OS) at Month 6
percentage of participantsPhase II MCLPhase II CLL
Phase II: Percentage of Participants With Overall Survival (OS) at Month 6NA (NA to NA)96.7 (87.3 to 99.2)
SecondaryPhase II: Plasma Concentration of Acalabrutinib

Blood samples were collected to determine the plasma concentration of acalabrutinib.

Time frame:
At 1, 2 and 4 hours post-dose on Day 8, 15 and 22 of Cycle 1
Reported as:
Geometric mean · nanogram per milliliter
Phase II: Plasma Concentration of Acalabrutinib
nanogram per milliliterPhase II MCLPhase II CLL
Cycle 1 Day 8: 1 hour157.3 ± 103.6238.7 ± 288.2
Cycle 1 Day 8: 2 hour155.0 ± 70.33187.2 ± 111.4
Cycle 1 Day 8: 4 hour77.06 ± 94.1958.73 ± 115.4
Cycle 1 Day 15: 1 hour160.3 ± 90.00206.6 ± 354.3
Cycle 1 Day 15: 2 hour178.9 ± 70.41195.7 ± 152.2
Cycle 1 Day 15: 4 hour61.31 ± 75.6049.96 ± 162.4
Cycle 1 Day 22: 1 hour196.3 ± 93.17—
Cycle 1 Day 22: 2 hour121.3 ± 87.67—
Cycle 1 Day 22: 4 hour100.8 ± 162.3—

Adverse events

Collected over Phase I and Phase II MCL: Treatment-emergent adverse events and all-cause mortality were reported from the first dose administration up to 30 days following the date of last dose of study treatment, approximately 25 months. Phase II CLL: Treatment-emergent adverse events and all-cause mortality were reported from the first dose administration up to 30 days following the date of last dose of study treatment, approximately 41 months. Assessed until DCO 18 December 2023.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I0/12 (0%)2/12 (16.7%)12/12 (100%)
Phase II MCL7/34 (20.6%)6/34 (17.6%)28/34 (82.4%)
Phase II CLL2/60 (3.3%)21/60 (35%)56/60 (93.3%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPhase IPhase II MCLPhase II CLL
Covid-19Infections and infestations0/120/346/60
Pneumonia fungalInfections and infestations1/120/340/60
Febrile neutropeniaBlood and lymphatic system disorders1/120/341/60
Covid-19 pneumoniaInfections and infestations0/120/345/60
PneumoniaInfections and infestations0/122/344/60
ThrombocytopeniaBlood and lymphatic system disorders0/121/340/60
Aplastic anaemiaBlood and lymphatic system disorders0/121/340/60
Inguinal herniaGastrointestinal disorders0/121/340/60
Multiple organ dysfunction syndromeGeneral disorders0/121/340/60
Gastrointestinal infectionInfections and infestations0/121/340/60
Most frequent other events
Showing 10 of 281
Most frequent other events
EventPhase IPhase II MCLPhase II CLL
Neutrophil count decreasedInvestigations4/127/3428/60
White blood cell count decreasedInvestigations5/123/343/60
Platelet count decreasedInvestigations4/1214/3424/60
AnaemiaBlood and lymphatic system disorders4/128/3414/60
HyperuricaemiaMetabolism and nutrition disorders4/125/348/60
PurpuraSkin and subcutaneous tissue disorders4/120/341/60
Covid-19Infections and infestations0/120/3416/60
Upper respiratory tract infectionInfections and infestations3/128/3411/60
HeadacheNervous system disorders3/127/3410/60
HaematuriaRenal and urinary disorders3/123/344/60

Baseline characteristics

The Safety analysis set included all participants who received at least 1 dose of acalabrutinib. A total of 105 unique participants were enrolled in the study.

Age, Categorical
Age, Categorical(Participants)Phase IPhase II MCLPhase II CLLTotal
<=18 years0000
Between 18 and 65 years7223766
>=65 years5112339
Sex: Female, Male
Sex: Female, Male(Participants)Phase IPhase II MCLPhase II CLLTotal
Female741930
Male5294175
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase IPhase II MCLPhase II CLLTotal
Asian123360105
08

Study locations

23 sites
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changzhou, 272100, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Fuzhou, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Hohhot, 10050, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Tianjin, 300020, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Ürümqi, 830054, China
  • Research Site
    Xining, 810007, China
  • Research Site
    Zhengzhou, 450008, China
09

References and documents

Publications

  • Yang S, Huang H, Zhou K, Zhao X, Han Y, Li L, Wang Y, Liu X, Li J. Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial. Ann Hematol. 2025 Jan;104(1):701-712. doi: 10.1007/s00277-024-05978-4. Epub 2024 Sep 14. PubMed 39271521 ↗
  • Song Y, Li J, Zhou K, Ke X, Cai Z, Zhang H, Yao T, Xia Z, Wang Y, Lai P, Liu X, Zhu J. Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma. Leuk Lymphoma. 2024 May;65(5):647-652. doi: 10.1080/10428194.2024.2310141. Epub 2024 Apr 1. PubMed 38557285 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Dec 2022, 31 months.

Results were first posted in Mar 2025, 2 years 2 months after primary completion.

Of 77 phase 1/2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 114. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2019
First posted
Apr 30, 2019
StartActual
Apr 29, 2020
Primary completionActual
Dec 22, 2022
CompletionEst.
Jun 24, 2026
Results first posted
Mar 20, 2025
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03932331
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 30, 2019
Start date
Apr 29, 2020
Primary completion
Dec 22, 2022
Completion
Jun 24, 2026 (estimated)
Results posted
Mar 20, 2025
Last update
Apr 20, 2026

Study contacts

Jun Zhu, Prof
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion